Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-TriCAR-SILK
- Development stage
- Unknown
- Lead developer
- Timmune Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19-TriCAR-SILK is an allogeneic, tri-functional chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Timmune Biotech for the treatment of CD19-positive B-cell malignancies, including B-cell leukemia and non-Hodgkin lymphoma. The therapy utilizes the "SILK" (Super-Innate Lymphocytes Killer) platform, which provides an "off-the-shelf" allogeneic NK cell product, making it a viable option for patients who are ineligible for autologous CAR-T therapy or leukapheresis. The TriCAR construct is engineered to simultaneously target CD19-expressing tumor cells via an anti-CD19 scFv, block inhibitory PD-L1 checkpoint signaling to overcome immune suppression, and provide a cytokine complex to stimulate the activation and expansion of both the CAR-NK cells and endogenous immune cells. It is currently in early Phase 1 clinical development, specifically targeting pediatric populations with relapsed or refractory disease.
- Other names
- CD19-TriCAR-NKCD-19-TriCAR-NKCD 19-TriCAR-NKCD19-TriCAR-T/SILK
02
Targets
CD19 (B lymphocyte antigen CD19)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on CD19-TriCAR-SILK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-TriCAR-SILK.